Mounjaro vs Trulicity
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| CA Mounjaro | CA Trulicity | |
|---|---|---|
| Generic name | tirzepatide | dulaglutide |
| Drug class | GIP/GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes | Type 2 diabetes |
| Category | Diabetes | Diabetes |
| Manufacturer | Eli Lilly | Eli Lilly |
| Year approved | 2022 | 2015 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $40M | $26M |
| Common side effects | Nausea, Diarrhea, Decreased appetite, Vomiting | Nausea, Diarrhea, Vomiting, Abdominal pain |
Trulicity
Frequently asked questions
Is Mounjaro or Trulicity better?
Neither is universally "better." Mounjaro (tirzepatide) and Trulicity (dulaglutide) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Mounjaro and Trulicity?
Mounjaro is a GIP/GLP-1 Receptor Agonist made by Eli Lilly, while Trulicity is a GLP-1 Receptor Agonist made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Mounjaro has the larger estimated TV advertising budget of the two.